Harrow, Inc. announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow?s rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow?s commitment to enhancing its leadership structure to support the Company?s continued growth.

John Saharek, Harrow?s Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow?s commercial business, focusing on the day-to-day management of Harrow?s market-leading compounded division. DiPasquale joins Harrow from Regeneron Pharmaceuticals, Inc., where he served as National Business Director and was responsible for key account management and national sales of the anti-VEGF products EYLEA® and EYLEA® HD for its two highest volume indications. Under his leadership, sales of products under Greg?s portfolio grew from $4.5 billion to over $6 billion during a four-year period.

Prior to this role, DiPasquale was Vice President and Head of Sales for the newly formed Retina Division of Novartis Ophthalmology, where he oversaw the development of the division?s sales infrastructure, spearheaded the launch of BEOVU®, and expanded the entire retina and ophthalmology product pipeline, generating over $1 billion in revenues in 2020. DiPasquale?s extensive experience also includes executive leadership positions at Bausch + Lomb as Vice President of Sales for the U.S. Vision Care business, at Zeiss Vision Care as Senior Vice President, with responsibility for profit and loss for its eyecare professional practice and the management of multiple lab operations and sales personnel throughout the U.S., and at Essilor USA. DiPasquale holds a Bachelor?s in Business Administration (BBA) from Ohio University and an Executive MBA from Kent State University.

DiPasquale will be based in Harrow?s Nashville, Tennessee, corporate headquarters.